Calamos Advisors LLC acquired a new stake in shares of Veracyte, Inc. (NASDAQ:VCYT – Get Rating) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 21,475 shares of the biotechnology company’s stock, valued at approximately $884,000. Several other hedge funds have also recently made changes to their […]
Veracyte, Inc. (NASDAQ:VCYT – Get Rating)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $29.52, but opened at $26.35. Veracyte shares last traded at $26.19, with a volume of 60,662 shares traded. A number of research firms have recently commented on VCYT. StockNews.com began coverage on […]
Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson
Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson
Veracyte, Inc. (Nasdaq: VCYT) today announced it has expanded its long-term strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson
1. The collaboration will include a focus on the NOBLE trial, a 9,000-patient, prospective, multicenter clinical study designed to distinguish genomic and other differences in lung cancer development and progression among patients with lung nodules detected by CT imaging. As Veracyte plans for the 2021 launch of the first noninvasive nasal swab test to guide the work-up of patients with potentially cancerous lung nodules, this new study will position the company to develop future tests that benefit broader patient populations, including nonsmokers and those with pre-cancerous changes who are likely to develop lung cancer.